BLU-448
/ Sanofi, Blueprint Medicines
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
Characterization of BLU-448: A potent and selective degrader of CDK4 for the treatment of HR+/HER2- breast cancers
(AACR 2026)
- "Abstract is embargoed at this time."
Late-breaking abstract • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • CDK4 • HER-2
1 to 1
Of
1
Go to page
1